Re-investigating PLK1 inhibitors as antimitotic agents

Abstract

Polo-like kinase 1 (PLK1) plays key roles during mitosis, prompting the development of PLK1 inhibitors for anticancer therapy. We recently determined that PLK1 is crucially required for entry into mitosis. Hence, we discuss the potential and limitations of PLK1 inhibition strategies to promote mitotic arrest and death of cancer cells.

Keywords

• polo-like kinase 1
• kinase inhibitor
• antimitotic
• g2 phase
• cancer